News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Scoping Review in Lancet Digital Health Highlights the Importance of Objective Cough Counting Data in Disease Management
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Wilmington, Del., Jan. 13, 2025 – A new scoping review published in The Lancet Digital Health examines the role of digital cough monitoring tools as objective, quantifiable measures of cough counts across a range of diseases. The review, which features global leader in AI cough care Hyfe, Inc., assesses the clinical practicality of continuous cough counting and its ability to address known limitations of patient-reported symptom data in real-world care settings.
The review, which pre-dates the release and adoption of Hyfe’s flagship clinical trial product CoughMonitor Suite, found that Hyfe’s cough-monitoring mobile app emphasizes the advantages of autonomous and continuous systems over contact-based ones, particularly when balancing real-world continuous monitoring with acceptable sensitivity (90 percent) and low false positives.
Led by Alexandra Zimmer, PhD, the review closely analyzed 77 studies evaluating digital cough monitoring tools, including Hyfe’s smartphone-based cough tracker app, now called CoughPro. Researchers looked at a variety of cough-counting platforms used in conditions such as asthma, chronic obstructive lung disease (COPD), chronic cough, tuberculosis, and COVID-19. The research team synthesized the different clinical and public health applications of these cough counting tools, assessed their alignment with patient-reported outcomes, and evaluated their readiness for broader implementation.
Key takeaways from the review include:
Patient-reported cough measures are valuable, but they are inherently subjective. Questions can be interpreted differently, recall varies, and for conditions that can be asymptomatic like tuberculosis, patients may not even perceive themselves as coughing at all. Objective monitoring offers a more consistent signal, which helps clinicians better understand disease activity and treatment response.
Dr. Alex Zimmer
McGill University
For Hyfe, these findings reinforce a growing consensus in respiratory medicine emphasizing objective data collection.
Objective, passive, and longitudinal monitoring tools are essential to complement subjective symptom reporting and help close the gap between clinical trials and everyday care. By combining objective data with patient experiences, we can improve therapeutic endpoint evaluation and enhance existing treatment protocols to better serve patients.
Peter Small
MD, CMO of Hyfe
To explore partnership opportunities or learn more about Hyfe’s digital therapeutic platform, visit hyfe.com or schedule a call here.
Hyfe, Inc. is the global leader in AI-powered cough-monitoring technology. The company’s patented machine-learning software enables passive, long-term monitoring of cough frequency, revealing novel health insights. Hyfe delivers cough-monitoring solutions that empower pharma and academic researchers to advance clinical trials, enable healthcare providers to optimize patient care, and power digital therapeutics to transform the management of respiratory illness, including chronic cough. Hyfe’s technology has been used in 50+ research studies, and its long-term partners include global pharma companies and leading academic institutions. More information is available at hyfe.com.
###
Media contact:
hyfe@ampublicrelations.com
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.